J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

Complex legal battle concerns ‘skinny label’ strategy used by generic drug makers, prompting a $235 million award | Pharma giant looks for enhanced damages due to ‘wilful infringement’, while opponent ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

A new cancer vaccine is being created to analyse how pre-cancerous cells develop to target the disease before it takes hold.

Sheryl Lee Ralph exclusively told Us Weekly she is ready to reunite with Denzel Washington for an 'adult rom-com' ...

In an exclusive interview with SheKnows, Sheryl Lee Ralph spoke about the importance of health discussions with your family!

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.